TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key repair process called homologous recombination, the cell uses loops in its ...

Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key repair process called ...

Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient ...

Expanding its Portfolio with American Amnion to Serve the Wound Care Needs of Our VeteransPOMPANO BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading ...

Inhibiting Fatty Acid Synthase Overcomes PARPi Resistance and Creates an Artificial Synthetic Lethality in Triple-Negative Breast Cancer ...

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

The Wyss Institute is proud to welcome three new Associate Faculty members: Ahmad (Mo) Khalil, Ph.D., Jarad Mason, Ph.D., and Chao-ting (Ting) Wu, Ph.D. Each has a history of collaborating with the ...